Related Experiment Videos

[Factors associated with hyperhomocysteinemia in Crohn's disease]

F Maire1, L Beaugerie, M Cohen

  • 1Service d'Hépato-Gastroentérologie, Hôpital Rothschild, Paris, France. laurent.beaugerie@rth.ap-hop-paris.fr

Insights

Over half of Crohn's disease patients exhibit hyperhomocysteinemia, a risk factor for thrombosis. Addressing modifiable factors like smoking and cobalamin deficiency is crucial for reducing thrombotic risk in these patients.

Area of Science:

  • Gastroenterology
  • Hematology
  • Metabolic Disorders

Context:

  • Inflammatory bowel disease (IBD), specifically Crohn's disease (CD), is linked to an increased incidence of thromboembolic events.
  • Hyperhomocysteinemia, elevated homocysteine levels, is a recognized risk factor for thrombosis.
  • Understanding the prevalence and associated factors of hyperhomocysteinemia in CD is vital for risk stratification and management.

Purpose:

  • To determine the prevalence of hyperhomocysteinemia in a cohort of patients with Crohn's disease.
  • To identify clinical and biological factors associated with hyperhomocysteinemia in this patient group.

Summary:

  • A study of 171 Crohn's disease patients revealed a 52% prevalence of hyperhomocysteinemia (mean homocysteine 14.8 µmol/L).
  • Hyperhomocysteinemia was significantly associated with older age, male sex, smoking, lower serum cobalamin, and prior ileal resection.
  • Multivariate analysis identified male sex and smoking as independent predictors of hyperhomocysteinemia.

Impact:

  • The high prevalence of hyperhomocysteinemia in Crohn's disease underscores the need for proactive screening and management.
  • Targeting modifiable risk factors such as smoking cessation and vitamin B12 (cobalamin) repletion can potentially mitigate thrombotic risk in CD patients.
  • These findings contribute to a better understanding of the pathophysiology linking Crohn's disease, hyperhomocysteinemia, and thrombosis.
Abstract

Related Concept Videos